Toxin activity results in fluid release or formation of ___.
edema
Once the bacteria enter the blood stream, they begin producing ___.
exotoxin
1/51
p.3
Mechanism of anthrax toxin action

Toxin activity results in fluid release or formation of ___.

edema

p.7
Mechanism of anthrax toxin action

Once the bacteria enter the blood stream, they begin producing ___.

exotoxin

p.5
Treatment options for cutaneous anthrax

Antibiotic therapy for cutaneous anthrax includes ___, ___, or ___ .

Ciprofloxacin, Penicillin, Doxycycline

p.6
Inhalational anthrax and its complications

In inhalational anthrax, the spores are inhaled and lodged in the ___ spaces.

alveolar

p.6
Mechanism of anthrax toxin action

The spores of inhalational anthrax survive ___ and germinate within the endosome.

phagocytosis

p.15
Inhalational anthrax and its complications

Pulmonary anthrax is also known as ___ disease.

Woolsorter's

p.15
Gastrointestinal anthrax symptoms and progression

Gastrointestinal anthrax occurs when spores reach the gastrointestinal tract after ___ contaminated animal meal.

ingesting

p.3
Mechanism of anthrax toxin action

EF has ___ activity similar to diphtheria pertussis toxin, increasing intracellular cAMP.

adenylate cyclase

p.8
Treatment options for cutaneous anthrax

Treatment is successful only if it begins before a critical concentration of ___ has accumulated.

toxin

p.7
Inhalational anthrax and its complications

Pulmonary anthrax results in massive pulmonary ___, haemorrhage and respiratory arrest.

edema

p.13
Laboratory diagnosis of anthrax

Mac Fadyean’s stain comprises ___ and ___ for staining.

Mercury chloride, polychrome methylene blue

p.14
Prevention and control measures for anthrax

Vaccination of ___, primarily cattle, is an important control measure for anthrax.

animals

p.10
Inhalational anthrax and its complications

Inhalational anthrax is difficult to treat because symptoms appear only after ___ has multiplied.

B. anthracis

p.11
Gastrointestinal anthrax symptoms and progression

The mortality rate for gastrointestinal anthrax is greater than ___%.

50

p.9
Treatment options for cutaneous anthrax

The antibiotics used for treating cutaneous anthrax are the same as those used for ___ anthrax.

cutaneous

p.9
Treatment options for cutaneous anthrax

Successful treatment of cutaneous anthrax requires timely intervention before the accumulation of ___ concentration.

toxin

p.2
Mechanism of anthrax toxin action

The ring acts like a ___ boring through the plasma membrane of the macrophage.

syringe

p.11
Gastrointestinal anthrax symptoms and progression

Symptoms of gastrointestinal anthrax appear ___ days after ingestion of undercooked meat.

2-5

p.4
Clinical manifestations of cutaneous anthrax

Skin infections from cutaneous anthrax initially resemble ___ bites.

insect

p.9
Treatment options for cutaneous anthrax

Treatment for cutaneous anthrax is successful only if it begins before a critical concentration of ___ has accumulated.

toxin

p.4
Clinical manifestations of cutaneous anthrax

The cutaneous form of anthrax accounts for more than ___% of naturally occurring anthrax.

95

p.14
Prevention and control measures for anthrax

People with a high occupational risk should be immunized with the cell-free vaccine obtainable from the ___.

CDC

p.12
Laboratory diagnosis of anthrax

Specimens for laboratory diagnosis include materials from the ___.

eschar

p.6
Inhalational anthrax and its complications

After germination, the bacteria spread to the regional ___ nodes and eventually to the blood stream.

lymph

p.8
Clinical manifestations of cutaneous anthrax

In the initial phase of the disease, symptoms include ___, malaise, non-productive cough, and some chest pain.

mild fever

p.16
Anthrax toxin components and their roles

Anthrax toxin is composed of three distinct materials: Protective antigen (PA), Lethal factor (LF), and ___ factor (EF).

Edema

p.3
Mechanism of anthrax toxin action

LF interferes with a transcription factor regulating numerous ___ and other immunity genes.

cytokines

p.4
Clinical manifestations of cutaneous anthrax

The incubation period of cutaneous anthrax is ___ days.

1-15

p.15
Clinical manifestations of cutaneous anthrax

Cutaneous anthrax infection occurs through entry of spores via a ___ or ___ on the skin.

cut, abrasion

p.14
Prevention and control measures for anthrax

Those who handle infected animals or their products are considered to have a ___ occupational risk.

high

p.12
Laboratory diagnosis of anthrax

The selective medium used for Bacillus is ___ medium.

PLET

p.12
Laboratory diagnosis of anthrax

Regular media such as blood agar and nutrient agar are used because the organism grows well on ___.

regular media

p.11
Gastrointestinal anthrax symptoms and progression

The primary lesions in gastrointestinal anthrax are ___, allowing B. anthracis to become blood-borne.

ulcerative

p.5
Treatment options for cutaneous anthrax

Without antibiotic treatment, mortality from cutaneous anthrax can be as high as ___%.

20

p.10
Inhalational anthrax and its complications

Even if antibiotics kill the bacteria, the ___ can still eventually kill the patient.

exotoxin

p.10
Epidemiology and fatality rates of inhalational anthrax

About ___ of the 18 cases of inhalation anthrax reported in the U.S. between 1900 and 1978 were fatal.

16

p.1
Pathogenesis of B. anthracis

For a successful infection, ___ must invade the host’s innate immune system by killing macrophages.

B. anthracis

p.5
Treatment options for cutaneous anthrax

Treatment for naturally-acquired cutaneous anthrax should continue for ___ to ___ days.

7, 10

p.8
Clinical manifestations of cutaneous anthrax

The second phase of the disease is characterized by a higher fever, acute dyspnoea, and ___.

cyanosis

p.17
Clinical manifestations of cutaneous anthrax

Cutaneous anthrax is primarily caused by the bacterium ___ ___ .

Bacillus anthracis

p.17
Clinical manifestations of cutaneous anthrax

The initial symptom of cutaneous anthrax is a small, raised ___ that develops into a sore.

bump

p.7
Epidemiology and fatality rates of inhalational anthrax

The medial lethal inhalation dose for humans has been estimated to about ___ spores.

8,000

p.1
Pathogenesis of B. anthracis

Macrophages have many anthrax toxin receptors on their plasma membranes to which the ___ portion of the exotoxin systematically attaches.

PA

p.1
Pathogenesis of B. anthracis

Attachment continues until ___ complexes gather in a doughnut-shaped ring.

7PA-ATK

p.17
Clinical manifestations of cutaneous anthrax

Cutaneous anthrax lesions typically develop into a characteristic ___ that is painless.

ulcer

p.16
Anthrax toxin components and their roles

None of the components of anthrax toxin is active alone; the combination of protective antigen and either of the other two antigens have ___ properties.

toxic

p.16
Anthrax toxin components and their roles

The three components of anthrax toxin are Protective antigen (PA), Lethal factor (LF), and Edema factor (EF), but only the combination of protective antigen with ___ or ___ has toxic properties.

Lethal factor, Edema factor

p.2
Mechanism of anthrax toxin action

Once inside the endosome, the PA molecules form a special ___ that pierces the endosomes’ membranes.

pore

p.2
Mechanism of anthrax toxin action

After binding ___ and ___, the entire complex is engulfed by the macrophages’ plasma membrane.

EF, LH

p.13
Laboratory diagnosis of anthrax

In a positive Mac Fadyean’s stain, the bacilli appear ___ in color, surrounded by ___ material.

blue, purplish

p.13
Laboratory diagnosis of anthrax

The basis for confirming the identity of the organism is ___.

PCR

Study Smarter, Not Harder
Study Smarter, Not Harder